Piramal Pharma Scores High on the S&P Global CSA
The S&P Global Corporate Sustainability Assessment (CSA) is an important annual evaluation that reviews the sustainability initiatives of numerous companies around the globe. It stands as one of the leading frameworks for evaluating corporate sustainability and highlights meaningful advancements in ecological and social governance.
Piramal Pharma's Remarkable Achievement
Piramal Pharma Limited (PPL) has announced a significant score of 63 in the 2025 S&P Global CSA, placing it within the 91st percentile among competitors in the pharmaceutical sector. This achievement reflects a substantial 15% increase from its previous score of 55, underscoring the company's intensified focus on responsible and sustainable operations.
Understanding the Score Increase
The improvement in PPL's score is a clear indicator of its commitment to sustainability. A higher score not only helps in building trust with stakeholders, customers, and partners but also boosts the company's reputation in the eyes of global investors. The evaluation criteria employed by S&P Global CSA encompass various aspects of ESG performance, governance maturity, and overall value creation.
Key Elements of PPL's Sustainability Strategy
PPL's significant progress can be attributed to its well-structured sustainability strategy, which operates on four foundational pillars: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity. Following this approach allows PPL to integrate ESG principles across all operational dimensions effectively, ensuring that the company not only meets but exceeds industry standards.
CEO's Vision
Peter DeYoung, CEO of Piramal Global Pharma, expressed, "Our progress on the S&P Global CSA underscores our unwavering dedication to responsible operations and sustainable growth. As we continue to expand, we remain committed to excellence in every aspect of our work, ensuring our work contributes to a healthier future for all." This reflects the leadership's vision for a greener and more sustainable approach to healthcare and pharmaceuticals.
Future Sustainability Initiatives
Capitalizing on the insights gleaned from the CSA, PPL aims to bolster its sustainability efforts even further. The company is not just committed to its progress but is also dedicated to encouraging its partners to foster positive change, thereby helping shape a more sustainable future for the pharmaceutical industry.
About Piramal Pharma Limited
Piramal Pharma Limited, abbreviated as PPL, is known for its diversified portfolio which spans across various sectors within pharmaceuticals. The organization operates through its numerous global development and manufacturing facilities, serving clients in over 100 countries. PPL encompasses areas including Piramal Pharma Solutions (PPS) and Piramal Critical Care (PCC), both of which hold important positions in their respective markets.
This extensive network positions PPL favorably to address the challenges and opportunities that arise within the pharmaceutical landscape. Furthermore, PPL is associated with various joint ventures, notably Abbvie Therapeutics India Private Limited, focusing on delivering innovative solutions in the healthcare sector.
Frequently Asked Questions
What does the S&P Global CSA evaluate?
The S&P Global CSA evaluates companies based on their sustainability practices, covering environmental, social, and governance (ESG) performance.
What was Piramal Pharma's score in the latest assessment?
Piramal Pharma scored 63 in the 2025 S&P Global CSA, marking a 15% improvement from the previous year.
What are the four pillars of PPL's sustainability strategy?
The pillars include Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity.
Who is the CEO of Piramal Pharma Limited?
The CEO of Piramal Pharma Limited is Peter DeYoung, who emphasizes sustainable growth and responsibility.
How does a higher CSA score benefit a company?
A higher CSA score enhances the organization's reputation, increases stakeholder trust, and attracts global investors.
